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Supplementary Materials and methods 
Purification and selection of aptamers for the SH2 domain of c-Src (Extended method) 
1. Expression in E. coli and Purification of GST-SH2, GST-SH3 and GST-SH2-SH3 
GST-SH2, GST-SH3 and GST-SH2-SH3 proteins containing human SH2 and SH3 human c-Src 
adapter domains were expressed, and soluble and insoluble fractions obtained. Both GST-SH2 and 
GST-SH3 were found in both insoluble and soluble fractions, while 100% of GST-SH2-SH3 was found 
in the insoluble fraction. GST-SH2 and GST-SH3 were purified from the soluble fraction by affinity 
chromatography with glutathione resin (Genescript). 
 
2. Selection of a population of aptamers against GST-SH2. 
Six rounds of selection were performed against GST-SH2, counteracting in round 3 and 5 with GST-
SH3 following the next selection conditions: Selection buffer PBS + 1 mM Mg; temperature 37°C; 
incubation of the protein with the aptamer in solution and immobilization with glutathione resin. 
The initial population (RND40) and rounds 3 and 6 were labelled with digoxigenin and the 
affinity of the populations for ELONA (Enzyme-Linked Oligonucleotide Assay) against GST-SH2 
and GST-SH3 was analyzed. 
 
 
Figure 1Aptamers. The affinity of the populations against GST-SH2 and GST-SH3 was analyzed for ELONA. 
GST-SH2 and GST-SH3 proteins were plated in a 96-well plate. The initial population (RND40) and rounds 3 
(SEL SH2 Rd3) and 6 (SEL SH2 Rd6) were labelled with digoxigenin and incubated in the presence of the 
proteins. 
 
Data show that a significant enrichment was achieved in Round 3, however, it was lost in 
Round 6. None of the populations recognized GST-SH3. Round 3 (SEL SH2 Rd3) was cloned. 
 
3.  Cloning and characterization of individual aptamers against each peptide. 
After cloning in the TA Cloning Kit (Invitrogen), 20 positive colonies were obtained. Plasmids were 
purified, individual aptamers amplified, and both strands were labelled with digoxigenin to check 
their affinity for ELONA. 
  
 
Figure 2 Aptamers. The affinity of the individual aptamers against GST-SH2 and GST-SH3 was analyzed for 
ELONA. GST-SH2 and GST-SH3 proteins were plated in a 96-well plate and the aptamers labelled with 
digoxigenin were incubated in the presence of the proteins. 
 
In view of these results, clones 2, 4, 5, 14, 17 and 20 were selected and sequenced. In addition, 
the individual chains F3-digoxigenin and R3-digoxigenin were labelled to assess which chain 
displayed higher affinity. 
 
 
Figure 3 Aptamers. The affinity of the individual aptamers (F-chain and R-chain) against GST-SH2 and GST-
SH3 was analyzed for ELONA. GST-SH2 and GST-SH3 proteins were plated in a 96-well plate and the aptamers 
labelled with digoxigenin were incubated in the presence of the proteins. 
 
The results show that clones 14, 17 and 20 were the aptamers with the highest affinity, the binding 
capacity of the F chain being higher than that of R. Furthermore, the analysis of the sequences shows 
that aptamers 14 and 20 corresponded to the same sequence. 
	
Figure 4 Aptamers. The structures obtained from in silico analysis of the aptamers ApSH2.14F and 
ApSH2.17F with the mFold and RNA fold programs as well as the presence of G-quadruplex 
analysed with QGRS mapper are shown. 
	
 
Immunofluorescence by lasers-scanning confocal microscopy  
Cells seeded on sterile coverslips were 72 h-treated with 0.2 µg/ml Doxy, fixed with 2% 
paraformaldehyde/PBS (15 min, room temperature), permeabilized with 0.5% Triton X100/PBS (10 
min, room temperature) and blocked 1 h with 10% normal goat serum/PBS. Coverslips were 
incubated overnight at 4°C with primary antibodies diluted 1:50 in 5% normal goat serum/PBS: 
mouse monoclonal anti-pY14-Caveolin 1 and rabbit polyclonal anti-pY418-Src. Coverslips were 
washed with PBS and then incubated for 1 h at 37°C with secondary antibodies diluted 1:200 in 5% 
normal goat serum/PBS: goat-anti-mouse IgG Alexa-Fluor 488 or goat-anti-rabbit IgG Alexa-Fluor 
546 (Life Technologies). After washing with PBS, cells were counterstained with DAPI (D1306, Life 
Technologies) in PBS (10 µg/ml) for 5min at room temperature, washed in PBS and coverslips 
mounted on slides with ProLong reagent (Life Technologies). Samples were analyzed by confocal 
microscopy. Images were acquired using an inverted Zeiss LSM 710 laser-scanning microscope with 
a Plan Apochromat 60x/1.40 objective. Sequential scanning mode was used to avoid crosstalk 
between channels. Z-optical stacks with 0.6 µm intervals through the cell Z-axis were recorded. 
Images were processed with ZEN 2009 software (Carl Zeiss AG) and Adobe Photoshop CS5 (Adobe 






Figure S1. Analyses of three generations Sphere Formation Efficiency (SFE). The sphere formation 
ability was analyzed in three consecutive generations of SUM159 and MDA-MB-231 cells 
conditionally expressing chicken c-Src variants. Each experiment was measured in triplicates and 
repeated three times. Results were expressed as percentage of mean +/- SD. 
 
 
Figure S2. Representative images of mammospheres of SUM159 and MDA-MB-231 cells expressing 
c-Src variants. 
 
Figure S3. Effect of conditional expression of SrcDN in SUM159 and MDA-MB-231 or suppression of 
endogenous c-Src in MDA-MB-231 on SFE. (A) SUM159 and (B) MDA-MB-231 that conditionally 
expressed SrcDN (chicken c-Src K295M/Y527F) and (C) MDA-MB-231 with conditional suppression 
of endogenous c-Src were tested for SFE. Each experiment was measured in triplicates and repeated 
three times. Results of the third generation were expressed as percentage of mean +/- SD, p<0.5*, 
0.01**, 0.001***. For each of these cell lines expression of c-Src, NANOG and Oct3/4 were determined 




Figure S4. Representative Western Blots images and analyses of ALDH1, NANOG and Oct3-4 from 




Figure S5. Soft-agar colonies from SUM159 and MDA-MB-231 cells expressing c-Src variants. 
 
 
Figure S6. Analyses of cell proliferation and Myc, cyclin D1, and p27Kip1 in Sum159 and MDA-MB-
231 cells expressing c-Src variants. Cells were cultured in absence (- Doxy = Control) or presence of 
Doxy (0.2 µg/mL) for 72h. Cells were then collected and analyzed as described in Material and 
methods. All the experiments were made in triplicates (N = 3). Results were expressed as mean +/- 
SD, p<0.5*, 0.01**, 0.001***. 
 
 
Figure S7. Cell cycle analyses of SUM159 and MDA-MB-231 cells expressing c-Src variants. SUM159 
and MDA-MB-231 cultured for 72h in absence or presence of Doxy (0.2 µg/mL) were trypsinized, 
collected by centrifugation and the pellet resuspended in 70% EtOH overnight at 4ºC. Cells were then 
resuspended in PBS containing RNase and propidium iodide and incubated at 37ºC. The analyses 
were made in CytoFlex S (Beckman-Coulter) cytofluorimeter using the FlowJo software (Becton 










Figure S8. Migration and invasion data of SUM159 and MDA-MB-231 cells expressing c-Src 
variants. The quantitation of the assays was made in reference to cells untreated with Doxy as 
Control. All the experiments were made in triplicates (N = 3). Results of three independent 




Figure S9. Kinetics curves of wound-healing assays of SUM159 and MDA-MB-231 cells expressing 
c-Src variants. 
 
Figure S10. Representative images of wound-healing assays of SUM159 and MDA-MB-231 cells 
expressing c-Src variants. 
 
 
Figure S11. Expression and activation of Caveolin 1, Paxillin and Fak in SUM159 and MDA-MB-231. 
Expression and degree of activation of focal adhesion proteins Caveolin 1, Paxillin and Fak was 
determined by WB, scanned and expressed as arbitrary units in SUM159 (A) and MDA-MB-231 (B) 
that conditionally expressed c-Src variants. Results represented data obtained from three 
independent WB (N = 3) using either b-Actin, a-Tubulin or GAPDH as loading control expressed as 
percentage of mean +/- SD, and were referred to those obtained from cells expressing c-Src-wt 




Figure S12. Expression and activation of Caveolin 1, Paxillin and Fak in SUM159 and MDA-MB-231. 
Expression and degree of activation of focal adhesion proteins Caveolin 1, Paxillin and Fak was 
determined by WB, scanned and expressed as arbitrary units in SUM159 (A) and MDA-MB-231 (B) 
that conditionally expressed c-Src variants. Results represented data obtained from three 
independent WB (N = 3) using either b-Actin, a-Tubulin or GAPDH as loading control expressed as 
percentage of mean +/- SD, and were referred to those obtained from cells untreated with Doxy             
(- Doxy = Control) considered as 1. The statistical significance is referred to cells expressing c-Src-wt, 





Figure S13. Representative WBs analyses of expression and activation of Caveolin 1, Paxillin and 




Figure S14. Western Blot analyses of total c-Src, Fak, phosphorylated pY397-Fak, pY576-Fak, and Akt 
and phosphorylated pS473-Akt from SUM159 and MDA-MB-231 cells expressing c-Src variants. Total 
cell extracts were prepared and WB analyses were made as described in Materials and methods. Since 
the intensity of the signals from WBs for pS473-Akt in SUM159 cell extracts were much more intense 
than those in MDA-MB-231, we reblotted this part of the membrane again with pS473-Akt antibody 









Figure S15. Confocal scanning microscopy analyses of pY14-Caveolin 1 and pY418-Src localization 
in SUM159 and MDA-MB-231 cells. Control, c-Src expressing variants SUM159 and MDA-MB-231 
were seeded in coverslips and then incubated with anti-pY14-Caveolin 1, anti-pY418-Src and DAPI 
as described in Supplementary methods and analyzed by scanning confocal microscopy at two levels, 
Basal layer for SUM159 and MDA-MB-231 cells respectively, and  Upper layer for SUM159 and MDA-





Figure S16. Kinetics curves of wound-healing assays of SUM159 and MDA-MB-231 cells. 
treated with aptamers 14F and 17F. 
 
Figure S17. Representative images of wound-healing assays of SUM159 and MDA-MB-231 cells 






Figure S18. Analyses by WB of expression of proliferation markers Myc, Cyclin D1, p27Kip1 and of 
migration Caveolin 1, Paxillin and Fak in SUM159 and MDA-MB-231 treated with aptamers.  
 
 











Authentication of SUM159PT and MDA-MB-231 cell lines by short-tandem-repeat analysis 
(GenePrintR 10 System from Promega, and GeneMapper v3.7 STR profile analysis software, Life 
Technologies) 
 








Western Blots for Mammospheres of SUM159 
 









Western Blots for Mammospheres of MDA-MB-231 
 
Uncropped gels corresponding to Fig. 2 D and Fig. S3 
 
MDA-MB-231-c-Src -WT -R175L -W118A/R175L



























 Uncropped gels corresponding to Figures 3, S7, 4, S9, S12 and S13. 






















Uncropped gels corresponding to Figures 3, S7, 4, S9, S12 and S13. 
SUM159-c-Src-R175L
























































Uncropped gels corresponding to Figures 3, S7, 4, S9, S12 and S13. 
 
  
Uncropped gels corresponding to Figures 3, S7, 4, S9, S12 and S13. 









































Uncropped gels corresponding to Supplementary Figure S14. 
Since the intensity of the pS473-Akt signals between SUM157 and MDA-MB-231 cells was too 
different, we reblotted again the part of the membrane corresponding to MDA-MB-231 samples 
with antibodies to pS473-Akt and b-Actin, as a loading control. 
 
